Three HLMs, A Host of Challenges and One Major Victory

For the last year, reforming the global health architecture in the hopes of delivering health more equitably has been top of mind. From the Pandemic Fund launch, to post-mortems on the ACT-A (the global body convened to develop COVID-19 interventions and ensure access to them), to the call for a new Pandemic Accord, a strong consensus had finally emerged that things need to change. 
 
Accordingly, this theme ran throughout the health-related proceedings at the UN General Assembly in September where High-Level Meetings (HLMs) on universal health care (UHC), Tuberculosis (TB), and Pandemic prevention, preparedness and response (PPPR) took place. 
 
Four key takeaways from the week stand out to AVAC:
 
Multilateralism is threatened.
Tensions between countries are incredibly high. Each day’s proceedings made clear that the spirit of diplomacy from previous years has waned. Given that there have already been UN Declarations on UHC and TB, advocates went into this year’s process thinking that stronger declarations would be relatively easy to negotiate. But countries were at odds during negotiations for all three health-related HLMs. Country representatives disagreed on a host of issues that will impact access to medical products, financing, and who is responsible for addressing health crises. These disagreements upended usual procedure. Typically, the Declaration is finalized weeks before the actual HLM; this year, a final decision on all three Declarations hung in the balance until the minute before the meetings began. Advocates must work hard in the coming year to bring countries together on key issues in the Pandemic Accord.
 
Access is THE issue.
By far, the question of access to medical products and tools dominated all three HLMs. Tensions around this issue sparked the most heated disagreements during negotiations. During the PPPR HLM, Member States speaking from the UN floor all mentioned their commitment to building more equitable access to medical countermeasures, but richer countries are unwilling to alienate the pharmaceutical industry by including access commitments in international agreements. And lower-income countries are refusing to permit open access to data on new pathogens without access commitments to the products derived from that data. The issue is so fraught it almost derailed any health Declarations at all. Right before HLM week, eleven countries that have been the target of ‘unilateral coercive measures’ (sanctions) sent a letter to the President of the General Assembly refusing to sign on to the declarations because the sanctions prevent them from accessing medical countermeasures — tools, medicines and equipment, needed in a health crisis. The Declarations ended up moving forward anyway with very limited commitments on how best to ensure access to medical countermeasures. It will be imperative for advocates to keep the issue of access front and center and help to navigate toward agreements that all countries can stomach.
 
Civil society engagement is going backward.
The PPPR HLM had no civil society formal engagement mechanism, and the process suffered because of it. Civil society was left out of the loop. They didn’t receive information about the status of negotiations, or details on sticking points. These updates would typically be funneled through a formal mechanism. In addition, the HLM process usually includes two to three days of Multistakeholder Hearings for each HLM to allow civil society to state their priorities and views ahead of negotiations on the draft Declaration. This year, each HLM had just one half-day, significantly limiting the number of civil society organizations and advocates that could get their views in front of Member States. Approvals for registration for both the Multistakeholder Hearings and HLMs came less than a month before the actual event, leaving many advocates too little time to get visas to the US. To add insult to injury, during the HLM, many civil society advocates did not get to make statements from the floor even though time was reserved for civil society – agencies such as Gavi and the Global Fund and pharmaceutical corporations spoke during these slots. Engagement with UN staff is needed to better define what constitutes civil society, and to protect these rare points of access and influence for those who speak for communities. 
 
Policymakers are starting to understand the contributions HIV, TB, and malaria can make to pandemic preparedness.
As the furor to address huge gaps in pandemic preparedness and response capacities ramped up in 2021, it was a slog to get policymakers new to the space, who had not traditionally been involved in health negotiations, to understand the underlying infrastructure and movements that the global responses to HIV, TB, and malaria have built. However, this year’s UN General Assembly showed that advocates have made a lot of progress. The Coalition of Advocates for Global Health and Pandemic Preparedness, of which AVAC is a co-founder, pushed hard for inclusion of these ongoing pandemics in the Declaration on PPPR to great success – two clauses recognizing the existing infrastructure from these responses that can be leveraged for pandemic preparedness and committing to continue the fight to end these ongoing pandemics made it into the final Declaration text. Much more needs to be done to harmonize the PPPR and HIV/TB/malaria architecture, saving advocates and everyone involved in pandemic preparedness extensive time and resources, but the recognition of the interconnectedness of future and ongoing pandemics represents a huge win.

At AVAC, we have put a lot of hope in the processes of the Pandemic Accord, the UN High-Level Meeting (HLM) on Prevention, Preparedness, and Response (PPPR), and the development of a medical countermeasures (MCM) platform. To understand how these three efforts fit together, see AVAC’s Advocate’s Guide to PPPR. 

And check out these other important resources:

Avac Event

Results from STI Landscaping Analyses in East and Southern Africa—Part 2

Thursday, November 9 at 8:00 AM ET

Hear results from STI landscaping projects conducted in seven different countries from East and Southern Africa that explored needs for STI vaccines and diagnostics.

Recording / Lesotho Network of AIDS Service Organizations (LENASO) Slides / HIV Survivors and Partners Network (HIVSPN) Slides / Pangaea Zimbabwe AIDS Trust (PZAT) Slides / Nyanza Reproductive Health Society (NRHS) Slides

Avac Event

Results from STI Landscaping Analyses in East and Southern Africa—Part 1

Tuesday, November 7 at 9:00 AM ET

Hear results from STI landscaping projects conducted in seven different countries from East and Southern Africa that explored needs for STI vaccines and diagnostics.

Recording / Latu Human Rights Foundation Slides / ACTS 101 Uganda Slides / Journalists Association Against AIDS (JournAIDS) Slides

Avac Event

Foundations of HIV Cure Research

In advance of the Strategies for an HIV Cure meeting, AVAC is hosting a foundational training for lay audiences interested in building their knowledge of HIV cure research. Through interactive sessions led by leading experts in the field, the meeting will provide attendees the ability to understand and translate basic science information.

The program will feature: Janet Siliciano, Deborah Persaud, Steven Deeks, Rebecca Lynch and David Margolis.

Recording of Dr. Janet Siliciano Presentation / Recording of Dr. Adam Ward Presentation / Recording of Dr. Deeks, Dr. Persaud, Dr. Joseph, Dr. Jones Presentation

Phase 1 mRNA HIV Vaccine Trials

A breakdown of current HIV mRNA trials and a primer on the basics of mRNA technology.

Avac Event

DoxyPEP Implementation – All Systems Go?

On October 5, The Choice Agenda (TCA) and the National Coalition of STD Directors (NCSD) hosted a discussion on the roll out of Doxycycline as STI PEP for helping gay, bisexual, and other men who have sex with men and transgender women reduce bacterial STIs, including gonorrhea, chlamydia, and syphilis.

Speakers:

Dr. Taimur Khan, Fenway Health
Cait Shea, NCSD
Kendrick Clack, NP, Crofoot MD Clinic/Research Center
Lee Vaughn-Ogin, Bigger Blacker Book

Recording / Slides / Resources

DPP Audience & Provider Insights for the DPP Research and Marketing Plan: Phase 1 Research Findings

This report, by M&C Saatchi World Services, AVAC, and partners, highlights learnings from Human-Centered Design Research undertaken in 2022 to understand the values and motivations of potential users and influencers of the Dual Prevention Pill (DPP) in Kenya, South Africa, and Zimbabwe.

Frequently Asked Questions About the Dual Prevention Pill (DPP)

This factsheet provides answers to the most frequently asked questions about the Dual Prevention Pill (DPP), including what it is, who might use it, and how it can be rolled out.

Announcing the New AVAC.org and Digital Resources

We are delighted to share the new and improved AVAC.org! On our new site, you can easily access all the great data, policy analysis, tools and resources that you’ve come to expect from AVAC, including our much-loved infographicspodcastsWeekly NewsDigest and Pandemic Watchwebinarsresearch literacy materials and so much more! 
 
The updated AVAC.org also reflects the expanded vision and practice of our dynamic programs. AVAC will always work to accelerate ethical development and equitable delivery of effective HIV prevention options. But, we also know that responding to HIV and preparing for future pandemics requires a comprehensive, integrated, and sustained response that is rights-based, people-centered and evidence-informed.
 
To AVAC, this means connecting the dots between HIV prevention, sexual and reproductive health and rights, pandemic preparedness, strengthened health systems, research engagement and community leadership. It means recognizing that resilience in global health requires us to confront the threats posed by disparities in access, entrenched stigma, discrimination, criminalizing key populations and inadequate responses to other sexually transmitted infections.

Visit the new AVAC.org for resources, tools and analysis that make these connections as we continue to track and translate the field, including:

  • Information on the entire pipeline of biomedical prevention strategies being investigated today
  • Our projects, which showcase the incredible partnerships and collaboration that underpin everything we do
  • Our podcast, PxPulse, which will deepen your knowledge and help you “check the pulse” of this fast-paced field and the urgent challenges still ahead
  • PxWire our quarterly update on where we are in biomedical prevention research
  • Our HIV clinical trials database, where you can find details on all biomedical prevention trials and our broader resource database containing fact sheets, infographics, blog posts and more on HIV prevention and the broader issues surrounding global health equity
  • Links to our newsletters—Pandemic WatchWeekly NewsDigest, and our Advocates Network

And be sure to check out three vital AVAC resources that give you all the information you need on PrEP accessSTI vaccine and diagnostics R&D and HIV prevention R&D funding.

We are immensely proud to share these resources with you. We hope these tools and analyses will help to power your advocacy, accelerate ethical development and equitable delivery of effective HIV prevention options, and advance global health equity.

Px Wire May 2023

Volume 13, Number 2

PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of PxWire.